Identifying the Optimal Number of Neoadjuvant Chemotherapy Cycles in Patients with Muscle Invasive Bladder Cancer.

David DAndrea,Peter C. Black,Homayoun Zargar,Colin P.N. Dinney,Francesco Soria,Michael S. Cookson,Jeffrey S. Montgomery,Wassim Kassouf,Marc A. DallEra,Srikala S. Sridhar,John S. McGrath,Jonathan L. Wright,Andrew C. Thorpe,Jeff M. Holzbeierlein,Diego M Carrion,Ettore Di Trapani,Trinity J. Bivalacqua,Scott North,Daniel A. Barocas,Yair Lotan,Petros Grivas,Andrew J. Stephenson,Bas W.G. van Rhijn,Siamak Daneshmand,Philippe E. Spiess,Shahrokh F. Shariat

Identifying the Optimal Number of Neoadjuvant Chemotherapy Cycles in Patients with Muscle Invasive Bladder Cancer.

2021

Purpose:We investigated the pathological response rates and survival associated with 3 vs 4 cycles of cisplatin-based neoadjuvant chemotherapy (NAC) in patients with cT2-4N0M0 muscle invasive bladd...

Keywords:

Neoadjuvant therapy
Oncology
Internal medicine
Chemotherapy
Bladder cancer
in patient
Cisplatin
Medicine
pathological response
muscle invasive

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations